18F-Florbetapir PET in Patients with Frontotemporal Dementia and Alzheimer Disease

Christopher Kobylecki, Tobias Langheinrich, Rainer Hinz, Emma Vardy, Gavin Brown, Elena Martino Casado, Cathleen Haense, Anna M Richardson, Alexander Gerhard, Jose Anton-Rodriguez, Julie Snowden, David Neary, Michael J Pontecorvo, Karl Herholz

Research output: Contribution to journalArticlepeer-review

Abstract

Pathologic deposition of amyloid beta (Abeta) protein is a key component in the pathogenesis of Alzheimer disease (AD) but not a feature of frontotemporal dementia (FTD). PET ligands for Abeta protein are increasingly used in diagnosis and research of dementia syndromes. Here, we report a PET study using (18)F-florbetapir in healthy controls and patients with AD and FTD. METHODS: Ten healthy controls (mean age +/- SD, 62.5 +/- 5.2 y), 10 AD patients (mean age +/- SD, 62.6 +/- 4.5), and 8 FTD patients (mean age +/- SD, 62.5 +/- 9.6) were recruited to the study. All patients underwent detailed clinical and neuropsychologic assessment and T1-weighted MR imaging and were genotyped for apolipoprotein E status. All participants underwent dynamic (18)F-florbetapir PET on a high-resolution research tomograph, and FTD patients also underwent (18)F-FDG PET scans. Standardized uptake value ratios (SUVRs) were extracted for predefined gray and white matter regions of interest using cerebellar gray matter as a reference region. Static PET images were evaluated by trained raters masked to clinical status and regional analysis. RESULTS: Total cortical gray matter (18)F-florbetapir uptake values were significantly higher in AD patients (median SUVR, 1.73) than FTD patients (SUVR, 1.13, P = 0.002) and controls (SUVR, 1.26, P = 0.04). (18)F-Florbetapir uptake was also higher in AD patients than FTD patients and controls in the frontal, parietal, occipital, and cingulate cortices and in the central subcortical regions. Only 1 FTD patient (homozygous for apolipoprotein E epsilon4) displayed high cortical (18)F-florbetapir retention, whereas (18)F-FDG PET demonstrated mesiofrontal hypometabolism consistent with the clinical diagnosis of FTD. Most visual raters classified 1 control (10%) and 8 AD (80%) and 2 FTD (25%) patients as amyloid-positive, whereas ratings were tied in another 2 FTD patients and 1 healthy control. CONCLUSION: Cortical (18)F-florbetapir uptake is low in most FTD patients, providing good discrimination from AD. However, visual rating of FTD scans was challenging, with a higher rate of discordance between interpreters than in AD and control subjects.
Original languageEnglish
Pages (from-to)386-391
Number of pages6
JournalJournal of nuclear medicine : official publication, Society of Nuclear Medicine
Volume56
Issue number3
Early online date1 Mar 2015
DOIs
Publication statusPublished - Mar 2015

Keywords

  • Alzheimer’s disease
  • PET
  • amyloid
  • diagnosis
  • frontotemporal dementia

Fingerprint

Dive into the research topics of '18F-Florbetapir PET in Patients with Frontotemporal Dementia and Alzheimer Disease'. Together they form a unique fingerprint.

Cite this